Kimmick, Gretchen
Dent, Susan
Klem, Igor
Article History
First Online: 31 May 2019
Compliance with Ethical Standards
:
: Gretchen Kimmick is on the Scientific Advisory Boards of Boehringer Ingelheim; Eisai [Epirubicin]; Genomic Health [OncotypeDX]; and Agendia [MammaPrint]; consulting/advising relationship with Genomic Health, AstraZeneca, Novartis, Pfizer; received Honoraria (speakers bureau) from Eisai; and Research Funding: Bionovo, PUMA, and Roche. Dr. Kimmick and group have participated, current and in past, in research funded by the following: Abbott Laboratories, AbbVie, Abraxis BioScience, Alphavax, AstraZeneca, Bionovo, BiPar Sciences, Bristol-Meyers Squibb, Celldex Therapeutics, Celsion, EMD Serono, Exelixis, Genentech, GlaxoSmithKline (CARG Trial), Incyte Corporation, Janssen, Johnson & Johnson Pharmaceuticals, Medimmune, Merck, Merrimack Pharmaceuticals, Mylan Pharmaceuticals, Myriad Genetics, Nektar Therapeutics, NRG Oncology, Novartis, Pfizer, Pharmacyclics, Roche Pharmaceuticals, Roxane Laboratories, Sanofi, Veridex LLC, and Wyeth.Susan Dent is on the advisory board for Hoffman La-Roche.Igor Klem declares no potential conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.